Iprozhin – progestin, corpus luteum hormone. By binding to receptors on the cell surface of bodies – target enters the nucleus where it activates DNA promotes RNA synthesis.
Mucosa promotes the transition from the phase endometrium proliferation induced follicular hormone in the secretory phase, and after fertilization – a condition necessary for the development of the fertilized ovum.
Reduces excitability and contractility of the muscles of the uterus and fallopian tubes, stimulates the development of the terminal,
mammary gland cells.
Stimulating proteinlipazu increases fat reserves, promote glucose utilization, increasing the concentration of basal and stimulated insulin promotes the accumulation of glycogen in the liver, increases the production of aldosterone; in small doses, faster, and more – suppresses the production of gonadotropic hormones of the pituitary; reduces azotemia, increases the excretion of nitrogen in urine. Activates the growth of secretory department of acini of the mammary glands and induces lactation. It contributes to the development of normal endometrium.
The ingestion well absorbed in the gastrointestinal tract, achieve time Cmax -. 1-3 hours after administration of 200 mg progesterone plasma concentration increases from 0.13 ng / ml to 4.25 ng / ml after 1 hour and was 11.75 ng / ml at 2 hours, 8.37 ng / ml – 3 hours, 2 ng / ml – 6 hours, 1.64 ng / ml – after 8 hours.
When applying intravaginaliom rapidly absorbed, high concentrations of progesterone is observed after 1 hour of plasma time to reach Cmax -. 2-6 h When administered 100 mg of 2 times / day average concentration -. 9.7 mg / ml within 24 h When administered more than 200 mg. progesterone concentration corresponds to I trimester of pregnancy. Relationship to plasma proteins – 90%.
It is metabolized in the liver with the participation of the enzyme CYP2C19 system. Major metabolites – 20-alpha-hydroxy-delta-4-alpha-pregnanolon and 5-alpha dihydroprogesterone. Excreted by the kidneys – 50-60%.
The active ingredient is:
Progesterone 200 mg
Premenstrual syndrome, fibrocystic breast disease; premenopausal, menopause, including premature, postmenopause – progestin component as hormone replacement therapy (HRT) in combination with estrogens
- tendency to thrombosis;
- acute forms of phlebitis or thromboembolic disorders;
- vaginal bleeding of unknown origin;
- incomplete abortion;
- or suspected malignancy of mammary glands and genitals;
- hypersensitivity to any of the ingredients of the drug.
Precautions: cardiovascular system, hypertension, chronic renal failure, diabetes, asthma, epilepsy, migraine, depression; hyperlipoproteinemia, lactation.
Drowsiness, dizziness, transient (1-3 h after administration), menstrual disorders (abbreviation intermediate bleeding).
How to accept, acceptance rate and dosage
Be sure to follow the recommended dosage, unless it is specified otherwise by your doctor.
Inside: the evening before going to bed (not recommended to be taken before, after or during meal times).
Premenstrual syndrome, fibrocystic mastopathy, dysmenorrhea, premenopausal – 200-300 mg within 10 days (17 to 26 day cycle); with hormone replacement therapy in postmenopausal women receiving estrogens on background – 200 mg / day for 10-12 days.
In the dark place at a temperature not higher than 25 ° C